These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700 [TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177 [TBL] [Abstract][Full Text] [Related]
11. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. Norlin AC; Remberger M Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840 [TBL] [Abstract][Full Text] [Related]
13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
14. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease. Melson J; Jakate S; Fung H; Arai S; Keshavarzian A Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511 [TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
16. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors. Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038 [TBL] [Abstract][Full Text] [Related]
17. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Kusumi E; Kami M; Yuji K; Hamaki T; Murashige N; Hori A; Kojima R; Kishi Y; Kim SW; Ueyama J; Miyakoshi S; Tanosaki R; Morinaga S; Mori S; Heike Y; Muto Y; Masuo S; Taniguchi S; Takaue Y Bone Marrow Transplant; 2004 Apr; 33(7):697-702. PubMed ID: 14755317 [TBL] [Abstract][Full Text] [Related]
18. Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns? Cho WK; Ahn MB; Lee JW; Chung NG; Jung MH; Cho B; Suh BK Bone Marrow Transplant; 2017 Jan; 52(1):144-146. PubMed ID: 27479687 [No Abstract] [Full Text] [Related]
19. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
20. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]